annual cash & cash equivalents:
$100.02M+$104.00K(+0.10%)Summary
- As of today (June 23, 2025), MDGL annual cash & cash equivalents is $100.02 million, with the most recent change of +$104.00 thousand (+0.10%) on December 31, 2024.
- During the last 3 years, MDGL annual cash & cash equivalents has risen by +$63.75 million (+175.77%).
- MDGL annual cash & cash equivalents is now -69.83% below its all-time high of $331.55 million, reached on December 31, 2022.
Performance
MDGL Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$183.65M+$83.63M(+83.61%)Summary
- As of today (June 23, 2025), MDGL quarterly cash & cash equivalents is $183.65 million, with the most recent change of +$83.63 million (+83.61%) on March 31, 2025.
- Over the past year, MDGL quarterly cash & cash equivalents has dropped by -$438.87 million (-70.50%).
- MDGL quarterly cash & cash equivalents is now -70.50% below its all-time high of $622.52 million, reached on March 31, 2024.
Performance
MDGL quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
MDGL Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.1% | -70.5% |
| 3 y3 years | +175.8% | +334.3% |
| 5 y5 years | +114.2% | +175.5% |
MDGL Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -69.8% | +175.8% | -70.5% | +334.3% |
| 5 y | 5-year | -69.8% | +175.8% | -70.5% | +447.5% |
| alltime | all time | -69.8% | >+9999.0% | -70.5% | >+9999.0% |
MDGL Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $183.65M(+83.6%) |
| Dec 2024 | $100.02M(+0.1%) | $100.02M(-57.0%) |
| Sep 2024 | - | $232.68M(-53.0%) |
| Jun 2024 | - | $494.60M(-20.5%) |
| Mar 2024 | - | $622.52M(+523.0%) |
| Dec 2023 | $99.92M(-69.9%) | $99.92M(+61.0%) |
| Sep 2023 | - | $62.05M(-19.6%) |
| Jun 2023 | - | $77.20M(-31.9%) |
| Mar 2023 | - | $113.31M(-65.8%) |
| Dec 2022 | $331.55M(+814.1%) | $331.55M(+458.7%) |
| Sep 2022 | - | $59.34M(+11.4%) |
| Jun 2022 | - | $53.27M(+26.0%) |
| Mar 2022 | - | $42.28M(+16.6%) |
| Dec 2021 | $36.27M(-32.8%) | $36.27M(-26.2%) |
| Sep 2021 | - | $49.17M(+46.6%) |
| Jun 2021 | - | $33.54M(-24.1%) |
| Mar 2021 | - | $44.20M(-18.1%) |
| Dec 2020 | $54.00M(+15.6%) | $54.00M(-50.5%) |
| Sep 2020 | - | $109.12M(+76.4%) |
| Jun 2020 | - | $61.87M(-7.2%) |
| Mar 2020 | - | $66.65M(+42.7%) |
| Dec 2019 | $46.70M(-18.6%) | $46.70M(-47.8%) |
| Sep 2019 | - | $89.49M(+23.4%) |
| Jun 2019 | - | $72.51M(+52.7%) |
| Mar 2019 | - | $47.49M(-17.2%) |
| Dec 2018 | $57.38M(-61.4%) | $57.38M(+50.8%) |
| Sep 2018 | - | $38.05M(-85.6%) |
| Jun 2018 | - | $264.86M(+594.7%) |
| Mar 2018 | - | $38.13M(-74.3%) |
| Dec 2017 | $148.63M(+676.3%) | $148.63M(+1046.8%) |
| Sep 2017 | - | $12.96M(-62.8%) |
| Jun 2017 | - | $34.80M(+323.6%) |
| Mar 2017 | - | $8.21M(-57.1%) |
| Dec 2016 | $19.14M(+6152.4%) | $19.14M(+128.1%) |
| Sep 2016 | - | $8.39M(-22.0%) |
| Jun 2016 | - | $10.76M(-74.9%) |
| Mar 2016 | - | $42.81M(>+9900.0%) |
| Dec 2015 | $306.20K | $306.20K(-99.3%) |
| Sep 2015 | - | $45.54M(+42.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $32.00M(-3.8%) |
| Mar 2015 | - | $33.26M(-27.7%) |
| Dec 2014 | $46.02M(-5.1%) | $46.02M(-32.8%) |
| Sep 2014 | - | $68.48M(-29.3%) |
| Jun 2014 | - | $96.81M(+86.1%) |
| Mar 2014 | - | $52.03M(+7.3%) |
| Dec 2013 | $48.49M(-40.5%) | $48.49M(+90.3%) |
| Sep 2013 | - | $25.48M(-24.6%) |
| Jun 2013 | - | $33.78M(-3.4%) |
| Mar 2013 | - | $34.96M(-57.1%) |
| Dec 2012 | $81.51M(+171.0%) | $81.51M(+176.9%) |
| Sep 2012 | - | $29.44M(+15.0%) |
| Jun 2012 | - | $25.59M(-25.9%) |
| Mar 2012 | - | $34.55M(+14.9%) |
| Dec 2011 | $30.07M(-3.9%) | $30.07M(+45.7%) |
| Sep 2011 | - | $20.64M(-20.3%) |
| Jun 2011 | - | $25.89M(+49.0%) |
| Mar 2011 | - | $17.37M(-44.5%) |
| Dec 2010 | $31.31M(-29.1%) | $31.31M(-10.3%) |
| Sep 2010 | - | $34.91M(-18.1%) |
| Jun 2010 | - | $42.61M(-26.4%) |
| Mar 2010 | - | $57.92M(+31.2%) |
| Dec 2009 | $44.16M(-15.2%) | $44.16M(+26.9%) |
| Sep 2009 | - | $34.80M(+9.2%) |
| Jun 2009 | - | $31.88M(-22.5%) |
| Mar 2009 | - | $41.16M(-20.9%) |
| Dec 2008 | $52.05M(-55.0%) | $52.05M(-10.9%) |
| Sep 2008 | - | $58.40M(-26.4%) |
| Jun 2008 | - | $79.38M(-20.0%) |
| Mar 2008 | - | $99.21M(-14.2%) |
| Dec 2007 | $115.58M(+243.1%) | $115.58M(+139.1%) |
| Sep 2007 | - | $48.34M(-25.1%) |
| Jun 2007 | - | $64.53M(-16.1%) |
| Mar 2007 | - | $76.88M(+128.2%) |
| Dec 2006 | $33.69M(+41.5%) | $33.69M(-19.4%) |
| Sep 2006 | - | $41.80M(+75.6%) |
| Dec 2005 | $23.81M(-44.3%) | $23.81M(-10.1%) |
| Mar 2005 | - | $26.49M |
| Dec 2004 | $42.74M(+18.5%) | - |
| Dec 2003 | $36.06M | - |
FAQ
- What is Madrigal Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Madrigal Pharmaceuticals quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
What is Madrigal Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of MDGL is $100.02M
What is the all time high annual cash & cash equivalents for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual cash & cash equivalents is $331.55M
What is Madrigal Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, MDGL annual cash & cash equivalents has changed by +$104.00K (+0.10%)
What is Madrigal Pharmaceuticals quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of MDGL is $183.65M
What is the all time high quarterly cash & cash equivalents for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly cash & cash equivalents is $622.52M
What is Madrigal Pharmaceuticals quarterly cash & cash equivalents year-on-year change?
Over the past year, MDGL quarterly cash & cash equivalents has changed by -$438.87M (-70.50%)